Latest Breaking News On - Company fatecontrol - Page 1 : comparemela.com

Mythic Therapeutics Presents Preclinical Data on MYTX-011, an Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting

Mythic Therapeutics Presents Preclinical Data on MYTX-011, an Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBrian fiskeCompany fatecontrolAmerican association for cancer researchAmerican associationCancer researchChief scientific officerViking global investorsFirst round

Mythic Therapeutics Presents Preclinical Data on Investigational cMET-Targeting Antibody-Drug Conjug

Data demonstrate higher internalization in cMET positive (cMET+) tumor cells and broader, more potent efficacy, including a greater than 3-fold increase in efficacy in mouse models of non-small cell lung cancer (NSCLC), as compared to other cMET-targeting ADCsData establish preclinical proof of concept for MYTX-011.

South koreaUnited statesNimish geraCritical rev clin lab sciCompany fatecontrolAmerican association for cancer research annual meetingMythic therapeuticsAmerican associationCancer research annualGilles gallantChief development officerVice presidentTargeting protein kinasesPoster sectionBoard numberAbstract number